BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop ...
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...
EST BioXcel Therapeutics (BTAI) trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
BioXcel Therapeutics Inc (NASDAQ:BTAI) stock has plummeted to a 52-week low, reaching a price level of just $2.53. With a market capitalization of just $8 million and EBITDA of -$74 million in the ...
Feb. 05, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback